Clinical Trial Update: Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring Yttrium-90 in combination with ipilimumab and nivolumab for uveal melanoma with liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Metastases
• Uveal Melanoma

Drugs mentioned

• Yttrium-90 (yttrium-90)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: David Minor, MD | Conditions: Uveal Melanoma, Hepatic Metastases | Phase 1, Phase 2 | Status: UNKNOWN